Skip to Content

Join the 'Plaque Psoriasis' group to help and get support from people like you.

Plaque Psoriasis News

Promising Results for Ixekizumab Against Psoriatic Arthritis

Posted 26 May 2017 by Drugs.com

FRIDAY, May 26, 2017 – A new drug might help ease the pain and disability of a form of arthritis often linked to psoriasis. According to Stanford University researchers, psoriatic arthritis is an inflammatory joint disorder tied to an out-of-control immune response. The disease affects about one in every 200 people and is often accompanied by the autoimmune skin disorder psoriasis. Psoriatic arthritis typically arises after the age of 30 and can bring stiffness, pain and swelling of the joints, leading to real disability if treatments don't help. The new study focused on more than 300 adult patients across 10 countries. These patients were no longer seeing an effect from standard biologic drugs or had never experienced a benefit in the first place. That's not uncommon. "Only about half of psoriatic arthritis patients who are given TNF inhibitors get better," study lead author Dr. Mark ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Taltz, Ixekizumab, Psoriatic Arthropathy

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

Health Tip: Caring for Nail Psoriasis

Posted 17 Apr 2017 by Drugs.com

-- Nail psoriasis causes pitting, discoloration and thickening of the nails. So how to take care of your nails if you have the condition? Here are suggestions from the National Psoriasis Foundation: Trim your nails as short as you can, since longer nails are more prone to everyday damage. Protect your nails from injury, which can worsen psoriasis symptoms. When washing dishes, cleaning or cooking, protect your hands with a pair of cotton gloves underneath vinyl or nitrile gloves (not latex). Talk to your doctor about corticosteroid injections and other possible treatments. Read more

Related support groups: Psoriasis, Plaque Psoriasis, Onychomycosis - Fingernail, Psoriatic Arthropathy

Men More Prone to Severe Psoriasis: Study

Posted 7 Apr 2017 by Drugs.com

THURSDAY, April 6, 2017 – Severe psoriasis is much more common in men than women, a new study from Sweden reports. Researchers reviewed data from more than 5,400 people in Sweden with the common skin disease. The study found that women had a significantly lower rate of severe psoriasis than men. This was true for all age groups and for all parts of the body except the head, where severity scores were about the same for both sexes. The discovery that men's psoriasis is often more serious helps explain a gender gap, with more men than women seeking psoriasis treatment, said study senior author Marcus Schmitt-Egenolf. He is a researcher at Umea University's Department of Public Health and Clinical Medicine. "These findings should motivate a gender perspective in the management of severe psoriasis and its comorbidities, such as cardiovascular and metabolic disease," Schmitt-Egenolf said in ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

FDA Approves Siliq (brodalumab) for Plaque Psoriasis

Posted 2 Mar 2017 by Drugs.com

February 15, 2017 – The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies. "Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of S ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Brodalumab, Siliq

Siliq Approved for Plaque Psoriasis

Posted 2 Mar 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – The injected drug Siliq (brodalumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe plaque psoriasis in adults. Siliq is approved for patients who've already failed to respond to other systemic therapies, the agency noted. The autoimmune disease – so-called because the immune system produces antibodies that attack the body's own tissues – causes thick, scaly patches of red skin. The drug is designed to inhibit the body's inflammatory response that plays a role in the development of plaque psoriasis, the FDA said in a news release. The disease occurs most often in people with a family history, usually between ages 15 and 35. Saliq was evaluated in clinical studies involving more than 4,300 people with moderate-to-severe plaque psoriasis. The most common side effects included joint pain, headache, fatigue, diarrhea, ... Read more

Related support groups: Methotrexate, Psoriasis, Plaque Psoriasis, Soriatane, Tazorac, Dovonex, Taclonex, Oxsoralen, Acitretin, Methoxsalen, Tazarotene, Calcipotriene, Resorcinol, Enstilar, Vectical, Anthralin, Psoriatec, Dritho-Scalp, Trexall, Taclonex Scalp

Immune Disorders Such as MS, Psoriasis May Be Tied to Dementia Risk

Posted 2 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – People with autoimmune diseases – conditions that cause a person's immune system to turn against the body – appear to have an increased risk of developing dementia, a new British study suggests. Researchers found that 18 out of 25 different autoimmune diseases, such as lupus, psoriasis or multiple sclerosis, "showed a statistically significant association with dementia," said study co-author Dr. Michael Goldacre. He's a professor of public health at the University of Oxford. But Goldacre and other experts stressed that the study didn't prove that autoimmune diseases cause dementia. The research only showed that these conditions are associated with a higher risk of dementia. Specifically, the study found that people with multiple sclerosis appeared to have nearly double the risk of dementia. Psoriasis was associated with a 29 percent increased risk of ... Read more

Related support groups: Multiple Sclerosis, Ischemic Stroke, Heart Disease, Psoriasis, Dementia, Alzheimer's Disease, Transient Ischemic Attack, Plaque Psoriasis, Chronic Spasticity, Ischemic Stroke - Prophylaxis, Spasticity, Ischemic Heart Disease, Psoriatic Arthropathy

Can Depression Up Odds for Arthritis Linked to Psoriasis?

Posted 24 Feb 2017 by Drugs.com

FRIDAY, Feb. 24, 2017 – Depression in people with the chronic inflammatory skin disease psoriasis increases the risk of getting the joint condition known as psoriatic arthritis by about 37 percent, new research indicates. The finding raises concerns because depression is not uncommon in people with psoriasis, according to the authors of the study in the Feb. 22 issue of the Journal of Investigative Dermatology. "For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis, and how we might detect it earlier in the disease course," senior investigator Dr. Cheryl Barnabe said in a journal news release. She is from the McCaig Institute for Bone and Joint Health and the O'Brien Institute for Public Health at the University of Calgary in Alberta. While the study found a connection between ... Read more

Related support groups: Depression, Rheumatoid Arthritis, Major Depressive Disorder, Psoriasis, Dysthymia, Plaque Psoriasis, Psoriatic Arthropathy

FDA Approves Injectable Psoriasis Drug for Tough Cases

Posted 16 Feb 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – A new drug to treat tough cases of the skin condition psoriasis has won approval from the U.S. Food and Drug Administration. Valeant Pharmaceuticals' injectable drug Siliq (brodalumab) was approved for adults with moderate-to-severe psoriasis that isn't responding to other recommended treatments. However, the drug carries a warning about increased risk for suicidal behavior. Psoriasis is characterized by raised patches of red skin and flaking. The condition usually begins between ages 15 and 35 and is thought to be an autoimmune disorder, meaning the body mistakenly attacks healthy cells. "Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today's approval provides patients with another treatment option for their psoriasis," said the FDA's Dr. Julie Beitz. Beitz is director of the Office of Drug ... Read more

Related support groups: Methotrexate, Psoriasis, Plaque Psoriasis, Soriatane, Tazorac, Dovonex, Taclonex, Oxsoralen, Acitretin, Methoxsalen, Tazarotene, Calcipotriene, Resorcinol, Enstilar, Vectical, Anthralin, Psoriatec, Dritho-Scalp, Trexall, Taclonex Scalp

Got an Itch? Use These Tips for Relief -- and Don't Scratch

Posted 31 Jan 2017 by Drugs.com

TUESDAY, Jan. 31, 2017 – Itchy skin is a common problem, but there are several ways to find relief, a dermatologist says. "There are many reasons for itchy skin," Dr. Hassan Galadari said in an American Academy of Dermatology news release. "It could be the result of a skin condition, such as eczema, shingles, hives or psoriasis, or it could be a sign of a contagious disease, like scabies or ringworm." To relieve itchy skin, Galadari offers these tips: Apply a cold, wet cloth or ice pack to the itchy area for five to 10 minutes or until the itch subsides. Or take an oatmeal bath. Use skin moisturizers that contain no additives, fragrances or perfumes. Apply topical anesthetics that contain pramoxine. Apply cooling agents such as menthol or calamine, or refrigerate your moisturizer to help achieve this cooling effect. Avoid scratching. It will irritate your skin and could lead to ... Read more

Related support groups: Skin Rash, Herpes Zoster, Psoriasis, Eczema, Scabies, Plaque Psoriasis, Calamine, Varicella-Zoster, Menthol, Pramoxine, Anusol, Calmoseptine, Biofreeze, Analpram-HC, Caladryl, Hydrocortisone/Pramoxine, Terocin, Sarna, Caladryl Clear, Dendracin

Weight Loss May Ease Psoriasis Symptoms, Study Finds

Posted 5 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 4, 2017 – Could weight loss combat psoriasis? Danish researchers are reporting that obese people with the skin condition who lose 10 percent to 15 percent of their weight may see significant and lasting improvement in their symptoms. The study participants lost an average of 33 pounds over 16 weeks. A year later, those who were still about 22 pounds below their weight from the start of the study maintained their improvements in psoriasis symptoms and quality of life, the study authors said. "Psoriasis is more than just a skin condition," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. Increased weight can stress the heart and other organs, and that stress can trigger psoriasis, she said. "We know that weight and psoriasis together and independently increase the risk of high blood pressure and heart disease and diabetes. Psoriasis is an ... Read more

Related support groups: Obesity, Weight Loss, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

Health Tip: Caring for Psoriasis on Your Feet

Posted 4 Jan 2017 by Drugs.com

-- Psoriasis causes red, scaly, itchy plaques on the skin, including the feet. The American Podiatric Medical Association suggests these ways to soothe it: Moisturize your feet regularly. Choose a moisturizer that's hypoallergenic and non-irritating. Soak feet in an oatmeal bath. Ask your doctor about special light therapy. Avoid psoriasis triggers, such as alcohol and exposure to dry air. See a podiatrist if your foot psoriasis doesn't improve. Read more

Related support groups: Psoriasis, Plaque Psoriasis, Dovonex, Tazorac, Taclonex, Oxsoralen, Resorcinol, Calcipotriene, Tazarotene, Anthralin, Enstilar, Vectical, Foot Care, Drithocreme, Avage, Taclonex Scalp, Dritho-Scalp, Psoriatec, Anthraforte, Psoriatic Arthropathy

Health Tip: Caring for Psoriasis During Winter

Posted 30 Dec 2016 by Drugs.com

-- Caring for psoriasis is a challenge during winter, when everyone's skin tends to become dry and itchy. The National Psoriasis Foundation says you should use products that: Are free of fragrance. Do not contain alcohol. Are made for sensitive skin. Do not aggravate skin. Products marked "natural" can still be irritating. Read more

Related support groups: Psoriasis, Plaque Psoriasis

FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis

Posted 13 Nov 2016 by Drugs.com

THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. "As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a need for FDA approved systemic therapies in the pediatric setting. Until now, no biologics — which are effective in treating adults with moderate-to-severe plaque psoriasis — had been approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in children," said Randy Beranek, president and chief executive officer of the National Psoriasis Foundation. "This new approval is an important dev ... Read more

Related support groups: Psoriasis, Enbrel, Plaque Psoriasis, Etanercept

Health Tip: Keep Psoriatic Arthritis Fatigue in Check

Posted 11 Nov 2016 by Drugs.com

-- Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have moderate-to-severe fatigue. The Foundation suggests: Exercise regularly to help ease pain and boost energy. Eat a nutritious, well-balanced diet. Get plenty of sleep. If you have a sleep disorder, seek treatment. Prioritize your to-dos, and pace yourself throughout the week. Read more

Related support groups: Fatigue, Psoriasis, Plaque Psoriasis, Psoriatic Arthropathy

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Psoriasis

Related Drug Support Groups

Humira, methylprednisolone, Enbrel, Remicade, dexamethasone, Otezla, hydroxyurea, Cosentyx, Dovonex, view more... infliximab, adalimumab, Taclonex, Taltz, etanercept, apremilast, calcipotriene, secukinumab, Enstilar, Inflectra, Taclonex Scalp, Erelzi, Amevive, Amjevita, ixekizumab, Renflexis, Sernivo, Siliq, Raptiva, betamethasone / calcipotriene, alefacept, efalizumab, brodalumab, Sorilux, Dovobet, Calcitrene